Clinical Trial

Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2025 (before its estimated March 23, 2026 completion). Its status may not reflect the trial's current state.
Summary
177Lu-LNC1004 Injection, a radiopharmaceutical targeting FAP, has demonstrated preliminary antitumor effect in advanced FAP-positive solid tumor patients. The primary purpose of this study is to evaluate the efficacy of 177Lu-LNC1004 Injection in patients with FAP-positive RAIR-DTC who have failed first-line TKIs treatment or refuse standard treatment. All subjects will receive 80 mCi (± 10%) 177Lu-LNC1004 Injection intravenously every 6 weeks for 2 cycles.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-21.
Trial Details
NCT Number NCT06898437
Lead Sponsor Peking Union Medical College Hospital
Conditions Radioiodine Refractory Differentiated Thyroid Cancer
Enrollment 20 participants
Start Date 2025-03-24
Primary Completion 2026-03-23 (estimated)
Study Completion 2027-03-23 (estimated)
Updated on ClinicalTrials.gov 2025-04-15